Featured Research

from universities, journals, and other organizations

Celecoxib Shows Surprising Activity Against Estrogen Receptors

Date:
December 23, 2004
Source:
M.D. Anderson Cancer Center, University Of Texas
Summary:
Six months of treatment with celecoxib (Celebrex) in women at risk of developing breast cancer results in the reduction of estrogen receptor expression in breast cells, a research team at The University of Texas M. D. Anderson Cancer Center has found.

Six months of treatment with celecoxib (Celebrex) in women at risk of developing breast cancer results in the reduction of estrogen receptor expression in breast cells, a research team at The University of Texas M. D. Anderson Cancer Center has found.

The surprising insight - that celecoxib may regulate a cell's use of estrogen - could help explain the drug's observed anticancer properties, says the study's lead author, Banu Arun, M.D., associate professor in the Department of Breast Medical Oncology.

"Since estrogen receptor expression is a marker of proliferation, this finding confirms celecoxib's antiproliferative properties," she says. "This is a preliminary, but exciting, finding that has not been reported in clinical chemoprevention studies before."

To date, the study has enrolled 40 women at high risk of developing breast cancer. Each woman agreed to undergo a fine needle aspiration and ductal lavage to remove breast epithelium cells both before and after six months of celecoxib treatment. These samples were available for analysis in 26 high-risk women. The researchers assessed the difference in estrogen receptor levels before and after treatment.

They found that the average pre- and post-treatment estrogen receptor expression was 30.8 percent and 21.8 percent, respectively, which is a statistically significant difference. Arun says they are continuing to examine the impact of celecoxib on other cancer risk markers in breast cells, such as EGFR, HER2, Ki-67 and Bcl-2.


Story Source:

The above story is based on materials provided by M.D. Anderson Cancer Center, University Of Texas. Note: Materials may be edited for content and length.


Cite This Page:

M.D. Anderson Cancer Center, University Of Texas. "Celecoxib Shows Surprising Activity Against Estrogen Receptors." ScienceDaily. ScienceDaily, 23 December 2004. <www.sciencedaily.com/releases/2004/12/041220024404.htm>.
M.D. Anderson Cancer Center, University Of Texas. (2004, December 23). Celecoxib Shows Surprising Activity Against Estrogen Receptors. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2004/12/041220024404.htm
M.D. Anderson Cancer Center, University Of Texas. "Celecoxib Shows Surprising Activity Against Estrogen Receptors." ScienceDaily. www.sciencedaily.com/releases/2004/12/041220024404.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins